top of page
  • Jonathan Poyer

AstraZeneca and Novartis Involved in Two M&A Deals - Momentum Factor Takes a Pause From Driving Equity Performance

Updated: Apr 11



The S&P Select Biotech Index moved back towards the 50-day moving average as the momentum factor took a pause from driving equity performance.



2 decent sized M&A deals took place this past week:


AstraZeneca acquired Amolyt Pharma for $800M (3/14/2024)

Novartis acquired IFM Due for $90M (3/13/2024)


Capital Market Highlights:


Week Ending 3/8/2024:


  • Biotech: 10 Transactions (6 Follow-Ons, 3 PIPEs, and 1 RD) totaling just under $2 Billion

  • Med Tech: No Current Week Transactions


2024 YTD:


  • 83 Biotech transactions totaling just under $16 Billion v 2023 YTD: 34 Biotech transactions totaling just under $4 Billion

  • 3 Med Tech transactions totaling just over $200 Million v 2023 YTD: 6 Med Tech transactions totaling just over


Private Transactions:


  • Biotech: 46 US Transactions / 16 European Transactions

  • Med Tech: 24 US Transactions / 11 European Transactions




14 views0 comments

Opmerkingen


bottom of page